KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Other Operating Expenses (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Other Operating Expenses for 13 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 240.58% to -$2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.1 million through Dec 2025, down 636.84% year-over-year, with the annual reading at -$1.8 million for FY2025, 169.71% down from the prior year.
  • Other Operating Expenses hit -$2.7 million in Q4 2025 for Arbutus Biopharma, down from $268000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.9 million in Q4 2024 to a low of -$12.0 million in Q2 2025.
  • Historically, Other Operating Expenses has averaged -$430950.0 across 5 years, with a median of $213000.0 in 2022.
  • Biggest five-year swings in Other Operating Expenses: soared 733.68% in 2022 and later crashed 5775.36% in 2025.
  • Year by year, Other Operating Expenses stood at $193000.0 in 2021, then skyrocketed by 733.68% to $1.6 million in 2022, then plummeted by 85.89% to $227000.0 in 2023, then surged by 732.6% to $1.9 million in 2024, then tumbled by 240.58% to -$2.7 million in 2025.
  • Business Quant data shows Other Operating Expenses for ABUS at -$2.7 million in Q4 2025, $268000.0 in Q3 2025, and -$12.0 million in Q2 2025.